Research Topics
Genomes and Genes | Mark SmythSummaryAffiliation: Peter MacCallum Cancer Centre Country: Australia Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Multiple functions of CXCL12 in a syngeneic model of breast cancerSHARON A WILLIAMS
School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia
Mol Cancer 9:250. 2010..To further elucidate its role in breast cancer progression, CXCL12 and its antagonist CXCL12(P2G) were overexpressed in the syngeneic 4T1.2 mouse model of breast carcinoma...
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in miceJennifer A Westwood
Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Australia
J Transl Med 8:42. 2010....
IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapyMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center, A Beckett Street, Victoria 8006, Australia
J Immunol 176:6347-55. 2006..These results indicate that a rational combination of Ab-based therapy that causes tumor cell apoptosis and a cytokine that promotes T cell memory is a useful new strategy for cancer immunotherapy...
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancerMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
J Immunol 176:1582-7. 2006..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancerMark J Smyth
Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, 8006, Victoria, Australia
J Exp Med 200:1325-35. 2004....
Activation of NK cell cytotoxicityMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, VIC 8006, Australia
Mol Immunol 42:501-10. 2005..This review will discuss the functional importance of NK cell cytotoxicity and the receptor/ligand interactions that control these processes...
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancerMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
J Exp Med 201:1973-85. 2005..Overall, the data suggest that NK cell antitumor function can be enhanced greatly by strategies that are designed to expand and differentiate NK cells via DC activation of NKT cells...
NKG2D function protects the host from tumor initiationMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Exp Med 202:583-8. 2005..These findings suggest an important early role for the NKG2D in controlling and shaping tumor formation...
Interleukin 21 enhances antibody-mediated tumor rejectionMark J Smyth
Cancer Immunology Program, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
Cancer Res 68:3019-25. 2008..These data further support the use of IL-21 in adjuvant settings where strong T cell-mediated immune responses to tumors can be generated...
IL-21 induces the functional maturation of murine NK cellsJason Brady
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
J Immunol 172:2048-58. 2004..These developmental changes suggested that IL-21 functions to induce the terminal differentiation of mouse NK cells, resulting in heightened NK cell-mediated cytotoxicity and immune surveillance...
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient miceErika Cretney
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, A Beckett Street, East Melbourne, 8006 Victoria, Australia
J Immunol 168:1356-61. 2002..TRAIL gene-targeted mice were also more sensitive to the chemical carcinogen methylcholanthrene. These results substantiated TRAIL as an important natural effector molecule used in the host defense against transformed cells...
Suppression of lymphoma and epithelial malignancies effected by interferon gammaShayna E A Street
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 8006, Australia
J Exp Med 196:129-34. 2002..A significant incidence of late onset adenocarcinoma observed in both IFN-gamma- and pfp-deficient mice indicated that some epithelial tissues were also subject to immunosurveillance...
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumorsNicole M Haynes
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, Royal Melbourne Hospital Research Foundation, A'Beckett Street, Victoria, Australia 8006
Blood 100:3155-63. 2002..Our study has illustrated the practical advantage of engineering a T-cell signaling complex that codelivers CD28 activation, dependent only upon the tumor's expression of the appropriate tumor associated antigen...
NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacyYoshihiro Hayakawa
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 172:123-9. 2004..These data suggested that NK cell TRAIL might regulate responses to vaccination by controlling the survival of Ag-loaded DC...
Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejectionMark J Smyth
Cancer Immunology Program, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
J Immunol 171:515-8. 2003....
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulationNicole M Haynes
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St. Andrew's Place, East Melbourne, Victoria, Australia
J Immunol 169:5780-6. 2002....
T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent mannerMichele W L Teng
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 8006, Australia
J Biol Chem 280:38235-41. 2005..Overall, this study demonstrated the significant potential of suppressing tumors and other cellular targets expressing NKG2D-L by endowing T cells with innate NK cell-like function...
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisJeremy B Swann
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
Proc Natl Acad Sci U S A 105:652-6. 2008..Overall, these data not only confirm the key role that MyD88 plays in promoting tumor development but also demonstrate that inflammation-induced carcinogenesis and cancer immunoediting can indeed occur in the same mouse tumor model...
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforinYoshihiro Hayakawa
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, A Beckett Street, St Andrews Place, East Melbourne, 8006 Victoria, Australia
J Immunol 169:5377-81. 2002..Thus, these results indicated that NKG2D acted as a natural cytotoxicity receptor to stimulate perforin-mediated elimination of ligand-expressing tumor cells...
Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesisYoshihiro Hayakawa
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne 8006, Australia
Proc Natl Acad Sci U S A 100:9464-9. 2003..Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis...
Combined natural killer T-cell based immunotherapy eradicates established tumors in miceMichele W L Teng
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Cancer Res 67:7495-504. 2007..In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment...
Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletionMichele W L Teng
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Cancer Res 70:2665-74. 2010..These studies reveal that Tregs control multiple redundant elements of the immune effector response capable of inhibiting tumor initiation and underscore the importance of effectively targeting these cells in any cancer immunotherapy...
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramideMark J Smyth
Cancer Immunology, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
Blood 99:1259-66. 2002....
NKT cells - conductors of tumor immunity?Mark J Smyth
Cancer Immunology, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
Curr Opin Immunol 14:165-71. 2002....
Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cellsShayna E A Street
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre Peter Mac, 8006, Victoria, Australia
J Exp Med 199:879-84. 2004..These results reflect a critical role for NK cells and gammadeltaTCR+ T cells in innate immune surveillance of B cell lymphomas, mediated by as yet undetermined pathway(s) of tumor recognition...
Distinct receptor repertoire formation in mouse NK cell subsets regulated by MHC class I expressionYoshihiro Hayakawa
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia, 3002
J Leukoc Biol 83:106-11. 2008....
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceJennifer A Westwood
Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St. Andrew's Place, Melbourne, Victoria 3002, Australia
Proc Natl Acad Sci U S A 102:19051-6. 2005..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastasesChristopher J Chan
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 184:902-11. 2010....
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancerMichael H Kershaw
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 173:2143-50. 2004..T cell adjuvant treatment of day 8 metastatic disease resulted in dramatic increases in survival of mice, and this survival was significantly greater than that afforded by either doxorubicin, 5-fluorouracil, or herceptin...
Characterizing the anti-tumor function of adoptively transferred NK cells in vivoHollie J Pegram
Cancer Immunology Program, Cancer Immunotherapy Research Laboratory, Peter MacCallum Cancer Centre, 14 St Andrews Place, East Melbourne, Vic, 3002, Australia
Cancer Immunol Immunother 59:1235-46. 2010..Overall, the results of this study have important implications for enhancing NK cell-based immunotherapies...
Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapyMichele W L Teng
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 8006, Australia
Hum Gene Ther 17:1134-43. 2006....
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulationNicholas D Huntington
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
J Immunol 178:4764-70. 2007..These data indicate that NK cells acquire KLRG1 on their surface during development, and this expression correlates with functional distinctions from other peripheral NK cells in vivo...
Functional analysis of granzyme M and its role in immunity to infectionLily I Pao
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 175:3235-43. 2005..These data confirm a role for GrzM in the host response to MCMV infection, but suggest that GrzM is not critical for NK cell-mediated cytotoxicity...
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cellsNadine Y Crowe
Department of Pathology and Immunology, Monash University, Central and Eastern Clinical School, Prahran, Victoria, Australia
J Immunol 171:4020-7. 2003..This study provides critical new insight into how NKT cells can have such a major impact on immune responses, lasting many days beyond the initial stimulation of these cells...
A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivoJanice M Kelly
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
J Immunol 168:4472-9. 2002..Our findings demonstrate a key role for IFN-gamma in innate and adaptive immunity triggered by CD80 expression on tumor cells...
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejectionJanice M Kelly
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria, Australia
Nat Immunol 3:83-90. 2002..Thus CD27-CD70 interactions provide a key link between innate NK cell responses and adaptive T cell immunity...
Differential antitumor immunity mediated by NKT cell subsets in vivoNadine Y Crowe
Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
J Exp Med 202:1279-88. 2005....
NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challengeAdam P Uldrich
Department Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
J Immunol 175:3092-101. 2005..In summary, this study significantly enhances our understanding of how NKT cells respond to primary and secondary antigenic challenge in vivo...
Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashionJoe Wei
Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Melbourne, Victoria, Australia
J Immunol 185:6013-22. 2010..These observations suggest that IAV infection of tumor cells may facilitate improved cross-presentation of tumor Ags and may be used to augment clinical vaccine efficacy...
CD1d-based combination therapy eradicates established tumors in miceMichele W L Teng
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 183:1911-20. 2009....
Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunityHenrik Søndergaard
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 183:7326-36. 2009....
Innate tumor immune surveillanceMark J Smyth
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002, Victoria, Australia
Adv Exp Med Biol 590:103-11. 2007
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytesMichele W L Teng
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
Hum Gene Ther 15:699-708. 2004..These preclinical studies are an important proof of principle that human T cells may be genetically redirected to tumors in cancer patients...
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasisMichele W L Teng
Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Proc Natl Acad Sci U S A 107:8328-33. 2010..Overall, these data indicate the general role that IL-23 plays in suppressing natural or cytokine-induced innate immunity, promoting tumor development and metastases independently of IL-17A...
New aspects of natural-killer-cell surveillance and therapy of cancerMark J Smyth
Cancer Immunology Laboratory, Trescowthick Research Laboratories, Research Division, Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, Melbourne 8006, Australia
Nat Rev Cancer 2:850-61. 2002
Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cellsMaria Moeller
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Cancer Res 67:11428-37. 2007..These data support the use of gene-modified CD4(+) Th1 and CD8(+) T cells for mediating a sustained antitumor response...
Type I IFN contributes to NK cell homeostasis, activation, and antitumor functionJeremy B Swann
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 8006 Victoria, Australia
J Immunol 178:7540-9. 2007..This study demonstrates that endogenous type I IFN is a central mediator of NK cell antitumor responses...
Granzyme M mediates a novel form of perforin-dependent cell deathJanice M Kelly
Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, 8006 Victoria, Australia
J Biol Chem 279:22236-42. 2004..These data raise the likelihood that granzyme M represents a third major and specialized perforin-dependent cell death pathway that plays a significant role in death mediated by NK cells...
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistAilsa J Frew
Cancer Immunology Program, The Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St Andrews Place, East Melbourne 3002, Victoria, Australia
Proc Natl Acad Sci U S A 105:11317-22. 2008..These data demonstrate that combination therapies involving HDACi and activators of the TRAIL pathway can be efficacious for the treatment of cancer in experimental mouse models...
Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491Ilia Voskoboinik
Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St 8006 and The Walter and Eliza Hall Institute for Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia
J Biol Chem 280:8426-34. 2005..Finally, after experimentally verifying an optimized three-dimensional model, we have made predictions on the impact of two inherited perforin mutations of the C2 domain on calcium-dependent lipid binding and cell lysis...
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejectionMaria Moeller
Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, East Melbourne, 8006, Victoria, Australia
Blood 106:2995-3003. 2005..Overall, this study has highlighted the therapeutic potential of using combined transfer of antigen-specific gene-modified CD8+ and CD4+ T cells to significantly enhance T-cell adoptive transfer strategies for cancer therapy...
Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathwayJennifer A Westwood
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, A'Beckett Street, East Melbourne, 8006 Victoria, Australia
J Immunol 172:757-61. 2004....
IFN-gamma-dependent recruitment of mature CD27(high) NK cells to lymph nodes primed by dendritic cellsSally V Watt
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, Victoria, Australia
J Immunol 181:5323-30. 2008..Thus, our results identify that CD27(high) NK cells are the dominant population recruited to the draining LN and NK cell recruitment requires endogenous IFN-gamma in coordinating with DC migration...
DX5/CD49b-positive T cells are not synonymous with CD1d-dependent NKT cellsDaniel G Pellicci
University of Melbourne, Department of Microbiology and Immunology, Parkville, Victoria, Australia
J Immunol 175:4416-25. 2005..In summary, our data demonstrate that DX5/CD49b is a poor marker for identifying CD1d-dependent NKT cells...
Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivoHollie J Pegram
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 181:3449-55. 2008..p. RMA-erbB2(+) lymphoma. In summary, these data suggest that use of genetically modified NK cells could broaden the scope of cancer immunotherapy for patients...
No requirement for TRAIL in intrathymic negative selectionErika Cretney
Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Int Immunol 20:267-76. 2008..These results, combined with the fact that aged C57BL/6 TRAIL(-/-) mice showed no signs of spontaneous autoimmunity, strongly indicate that intrathymic negative selection occurs normally in the absence of TRAIL signaling...
CD1d activation and blockade: a new antitumor strategyMichele W L Teng
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Immunol 182:3366-71. 2009..The ability of anti-CD1d mAbs to coincidently activate CD1d(+) APCs to release IL-12 and inhibit CD1d-restricted type II NKT cells makes CD1d an exciting new target for immunotherapy of cancer based on tumor immunoregulation...
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitisJonathan M Coquet
Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
J Immunol 180:7097-101. 2008..Thus, our results challenge the notion that IL-21 is a key factor in driving Th17 immunity and disease...
Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinomaShayna E A Street
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Cancer Res 67:5454-60. 2007..This data suggests that perforin may mediate some suppression of epithelial carcinogenesis by intervening early in the tumor development process...
Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cellsIrina Caminschi
Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia
J Exp Med 204:2579-90. 2007..Thus, IKDCs resemble NK cells functionally, and neither cell type could be induced to be effective antigen-presenting cells...
Nature's TRAIL--on a path to cancer immunotherapyMark J Smyth
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
Immunity 18:1-6. 2003....
Normal thymocyte negative selection in TRAIL-deficient miceErika Cretney
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
J Exp Med 198:491-6. 2003..We were unable to demonstrate a role for TRAIL signaling in any of these models, suggesting that this pathway is not a critical factor for thymocyte negative selection...
A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cellsMaria Moeller
Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria, Australia
Cancer Gene Ther 11:371-9. 2004....
Innate immune recognition and suppression of tumorsYoshihiro Hayakawa
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria 3002, Australia
Adv Cancer Res 95:293-322. 2006..Evidence clearly implicate that NKG2D recognition plays an important role in tumor immune surveillance...
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcomeLinda Mileshkin
Division of Haematology and Medical Oncology, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center, St Andrew s Place, East Melbourne, Vic, Australia
Haematologica 92:1075-82. 2007..We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential prognostic markers and looked for changes with therapy...
Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodominationWeisan Chen
T Cell Laboratory, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
J Immunol 173:5021-7. 2004..We further show that immunodomination of PA(224-233)-specific TCD8+ by nucleoprotein 366-374-specific TCD8+ plays a critical role in the phenomena, and that this is unlikely to be mediated by TCD8+ lysis of APCs or other cells...
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stageDaniel G Pellicci
Department of Immunology and Pathology, Monash University Medical School, Prahran, Victoria 3181, Australia
J Exp Med 195:835-44. 2002..1(-). Further elucidation of this NKT cell developmental pathway should prove to be invaluable for studying the mechanisms that regulate the development of these cells...
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liverKazuyoshi Takeda
Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bukyou ku, Tokyo 113 8421, Japan
Blood 105:2082-9. 2005..This study is the first to describe the concomitant maturation of NK cell effector function with surface phenotype in vivo and implies an important defense role for NK cell TRAIL in the developing immune system...
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforinNaoko Seki
Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
J Immunol 168:3484-92. 2002..Therefore, although granule-mediated killing is of paramount importance for CTL-mediated lysis in vitro, some major in vivo effector mechanisms clearly are independent of perforin...
Eradication of established tumors in mice by a combination antibody-based therapyTomoyasu Uno
Department of Immunology, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan
Nat Med 12:693-8. 2006..These results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans...
IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2Tsuyoshi Ota
Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
Blood 106:184-92. 2005....
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor developmentKazuyoshi Takeda
Department of Immunology, Juntendo University, School of Medicine, Bunkyo ku, Tokyo 113 8421, Japan
J Exp Med 195:161-9. 2002..Moreover, development of spontaneous tumors in p53(+/-) mice was also promoted by neutralization of TRAIL. These results indicated a substantial role of TRAIL as an effector molecule that eliminates developing tumors...
IL-21 enhances tumor rejection through a NKG2D-dependent mechanismRayna Takaki
Department of Microbiology and Immunology, Biomedical Sciences Graduate Program and The Cancer Research Institute, University of California, San Francisco, CA 94143, USA
J Immunol 175:2167-73. 2005..Collectively, these findings suggest that IL-21 therapy may work optimally against tumors that can elicit a NKG2D-mediated immune response...
Calreticulin exposure increases cancer immunogenicityChris Clarke
Nat Biotechnol 25:192-3. 2007
Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivoAtsushi Tajima
Department of Immunology and Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo, Japan
J Immunol 171:1715-21. 2003..These results suggested a role for blastocyst MHC in protecting TAP-deficient trophoblasts and tumor cells from NK cell attack in vivo...
NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogsEdward S Morris
Queensland Institute of Medical Research, Brisbane, Queensland, Australia
J Clin Invest 115:3093-103. 2005....
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomasClaudia Curcio
Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy
J Clin Invest 111:1161-70. 2003..Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185(neu) carcinomas involves distinct mechanisms, each endowed with a different curative potential...
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancerNaoko Seki
Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702 1201, USA
Cancer Res 63:207-13. 2003..Consequently, the efficacy of TRAIL therapy may vary depending on the location of the tumor metastases...
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector functionKaren Abdool
Laboratory of Experimental Immunology, National Cancer Institute Frederick, Building 560, Frederick, MD 21702, USA
J Immunol 177:2575-83. 2006....
Functional interactions between dendritic cells and NK cells during viral infectionDaniel M Andrews
Department of Microbiology, School of Biomedical and Chemical Sciences, The University of Western Australia, Nedlands, Perth, Australia
Nat Immunol 4:175-81. 2003..This study provides evidence for a functional interrelationship between DCs and NK cells during viral infection and defines some of the critical cytokines...
NK cells contribute to the early clearance of HSV-1 from the lung but cannot control replication in the central nervous system following intranasal infectionPatrick C Reading
Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia
Eur J Immunol 36:897-905. 2006....
Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cellsTrina J Stewart
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia
Cancer Res 63:3058-60. 2003..This suggests that recruitment/activation of J alpha 18(+) NKT cells is an important consideration during the immune therapy of early stage tumors...
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasisAmanda C Stanley
Immunology and Infection Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia
PLoS Pathog 4:e1000028. 2008..Our data clearly illustrate the double-edged sword of NKT cell-based therapy, showing that in some circumstances, such as when sub-clinical or chronic infections exist, iNKT cell activation can have adverse outcomes...
IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramideYoshihiro Hayakawa
Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan
Blood 100:1728-33. 2002..These results suggest that the IFN-gamma-mediated inhibition of tumor angiogenesis is critically involved in the effector mechanisms of antitumor effects evoked by alpha-GalCer...
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomasNadine Y Crowe
Department of Pathology and Immunology, Monash University Medical School, Melbourne, Victoria 3181, Australia
J Exp Med 196:119-27. 2002....
Research Grants
- The regulation of tumor immunity by NKT cellsMark Smyth; Fiscal Year: 2007..This proposal focuses clearly on a pivotal immune control mechanism that will influence many current and future immunotherapies. ..
